Lirafugratinib
| CAS No. | 2549174-42-5 | Cat. No. | BCP49189 |
| Name | Lirafugratinib | ||
| Synonyms | FGFR2-IN-3;RLY-4008;RLY4008;RLY 4008; | ||
| Formula | C28H24FN7O2 | M. Wt | 509.55 |
| Description | Lirafugratinib is an orally bioavailable inhibitor of the fibroblast growth factor receptor 2 (FGFR2), with potential antineoplastic activity. Upon oral administration, lirafugratinib binds to and inhibits FGFR2, which results in the inhibition of FGFR2-mediated signal transduction pathways. This inhibits the proliferation of FGFR2-overexpressing tumor cells. FGFR2, a receptor tyrosine kinase upregulated in many tumor cell types, plays a key role in cellular proliferation, migration and survival. | ||
| Pathways | Angiogenesis/Protein Tyrosine Kinase | ||
| Targets | FGFR | ||
Structure
Part data of this page collected from the open network resources, so Biochempartner can not guarantee its accuracy.
For product details of different batches, please contact our Customer
- Service & Tech Support:orders@biochempartner.com
- Website:www.biochempartner.com
Products are for research use only and not for human use. We do not sell to patients.